<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Smooth Muscle Regulation - Section III.E</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }
        
        body {
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, 'Helvetica Neue', Arial, sans-serif;
            background: linear-gradient(135deg, #1e3c72 0%, #2a5298 100%);
            color: #2c3e50;
            padding: 20px;
            line-height: 1.6;
        }
        
        .container {
            max-width: 1400px;
            margin: 0 auto;
            background: white;
            border-radius: 15px;
            padding: 40px;
            box-shadow: 0 20px 60px rgba(0,0,0,0.2);
        }
        
        .header {
            text-align: center;
            margin-bottom: 30px;
            padding-bottom: 20px;
            border-bottom: 3px solid #1e3c72;
        }
        
        .header h1 {
            font-size: 2.5em;
            color: #1e3c72;
            margin-bottom: 10px;
            font-weight: 700;
        }
        
        .section-title {
            font-size: 1.8em;
            color: #1e3c72;
            margin: 30px 0 20px 0;
            font-weight: 600;
        }
        
        .clinical-box {
            background: #f0f8ff;
            border: 2px solid #4682b4;
            border-radius: 12px;
            padding: 25px;
            margin: 30px 0;
        }
        
        .clinical-box h3 {
            color: #1e3c72;
            font-size: 1.4em;
            margin-bottom: 15px;
            display: flex;
            align-items: center;
            gap: 10px;
        }
        
        .clinical-box p {
            line-height: 1.8;
            color: #34495e;
            text-align: justify;
        }
        
        .regulation-content {
            margin: 30px 0;
        }
        
        .regulation-content p {
            line-height: 1.8;
            margin-bottom: 15px;
            text-align: justify;
        }
        
        .regulation-item {
            background: #f8f9fa;
            border-left: 4px solid #3498db;
            padding: 20px;
            margin: 20px 0;
            border-radius: 8px;
        }
        
        .regulation-item h4 {
            color: #1e3c72;
            font-size: 1.3em;
            margin-bottom: 12px;
        }
        
        .highlight-box {
            background: linear-gradient(135deg, #fff3cd 0%, #ffeaa7 100%);
            border: 2px solid #ffc107;
            border-radius: 12px;
            padding: 20px;
            margin: 25px 0;
            text-align: center;
        }
        
        .highlight-box p {
            color: #856404;
            font-size: 1.1em;
            font-weight: 600;
        }
        
        .key-point {
            background: #e8f5e9;
            border-left: 4px solid #4caf50;
            padding: 15px;
            margin: 20px 0;
            font-style: italic;
        }
        
        .abbreviation {
            color: #e74c3c;
            font-weight: 600;
        }
    </style>
</head>
<body>
    <div class="container">
        <div class="header">
            <h1>III.E. Regulation of Smooth Muscle Contraction</h1>
        </div>

        <div class="regulation-content">
            <p>
                In striated muscle, force regulation usually occurs through control of intracellular Ca<sup>2+</sup> concentration. 
                In smooth muscle, force is regulated via changes in MLC<sub>20</sub> phosphorylation state. Force development 
                is dependent on crossbridge formation, which can only occur when MLC<sub>20</sub> is phosphorylated. Because 
                MLC<sub>20</sub> phosphorylation state is dependent on Ca<sup>2+</sup>, MLCK, and MLCP, there are multiple 
                potential control points. Three principal regulatory pathways involve <span class="abbreviation">ROCK</span> 
                (Rho-associated coiled-coil containing protein kinase, or Rho-kinase), <span class="abbreviation">protein kinase C (PKC)</span>, 
                and, in some tissues, <span class="abbreviation">protein kinase G (PKG)</span>.
            </p>
        </div>

        <div class="regulation-item">
            <h4>1. Rho-kinase (ROCK)</h4>
            <p>
                ROCK is a serine-threonine protein kinase regulated by RhoA, a G protein. RhoA is activated indirectly following 
                GPCR binding by, for example, norepinephrine, angiotensin II, endothelin, or any of a number of other ligands. 
                ROCK has several targets, including MYPT1. Phosphorylation inhibits MLCP and thereby promotes contraction. 
                ROCK also has MLCK-like activity and stimulates contraction through direct effects on MLC<sub>20</sub>. 
                Note that this pathway acts independently of any changes in sarcoplasmic Ca<sup>2+</sup> concentration.
            </p>
        </div>

        <div class="regulation-item">
            <h4>2. Protein kinase C (PKC)</h4>
            <p>
                Agonists that activate phospholipase C and promote contraction via IP<sub>3</sub> simultaneously activate PKC. 
                PKC also phosphorylates many proteins that regulate contraction, including CPI-17 (PKC-potentiated inhibitor 
                protein of 17 kDa). CPI-17 is an endogenous protein that binds to the PP1c MLCP catalytic domain and inhibits it, 
                thereby promoting contraction. ROCK also phosphorylates CPI-17 in vitro, but the possible significance for 
                smooth muscle function in vivo is unclear.
            </p>
        </div>

        <div class="highlight-box">
            <p>
                ROCK- and PKC-mediated contractility increases account for a phenomenon known as "Ca<sup>2+</sup> sensitization." 
                Ca<sup>2+</sup> sensitization refers to an observed shift in the Ca<sup>2+</sup> dependence of contractility 
                toward lower intracellular free Ca<sup>2+</sup> values following hormone or transmitter binding.
            </p>
        </div>

        <div class="regulation-item">
            <h4>3. Protein kinase G (PKG)</h4>
            <p>
                PKG is activated by cGMP, which is the product of guanylyl cyclase (GC). In vascular smooth muscle, 
                nitric oxide (NO) activates a soluble GC, which stimulates the activity of a PKG isoform common to 
                smooth muscle (PKG1α). PKG-1α binds to a carboxyterminal leucine zipper domain on MYPT1, activating it 
                and promoting smooth muscle relaxation. Expression of the PKG-sensitive MLCP may be limited to vascular 
                smooth muscle because NO has no effect on most other smooth muscle types.
            </p>
        </div>

        <!-- Smooth Muscle Regulation PNG Image Section -->
        <div style="text-align: center; margin: 30px 0; padding: 25px; background: #f8f9fa; border-radius: 15px; box-shadow: 0 8px 20px rgba(0,0,0,0.1); border: 2px solid #e9ecef;">
            <img src="smooth_muscle_regulation.png" alt="Smooth Muscle Regulation Mechanisms" 
                 style="max-width: 100%; height: auto; border-radius: 12px; box-shadow: 0 10px 25px rgba(0,0,0,0.15);">
            <p style="font-size: 1.1em; color: #6c757d; margin-top: 18px; font-style: italic; font-weight: 600;">
                Comprehensive regulation pathways of smooth muscle contraction showing Ca²⁺ sensitization and pharmacological control mechanisms
            </p>
        </div>

        <div class="key-point">
            <strong>Key Point:</strong> MLCK = myosin light-chain kinase; MLCP = myosin light-chain phosphatase; 
            MYPT1 = MLCP myosin-binding subunit; NO = nitric oxide; PKC = protein kinase C; PKG-1α = protein kinase G1α; 
            PP1c = MLCP protein phosphatase subunit; ROCK = Rho-kinase.
        </div>
    </div>
</body>
</html>